CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

NCT05207722 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped for business reasons

Conditions

Metastatic HER2 Positive Gastroesophageal Junction Cancer

Interventions

BIOLOGICAL: CYNK-101
DRUG: Pembrolizumab
DRUG: Trastuzumab
DRUG: Recombinant Human Interleukin-2
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Mesna

Sponsor

Celularity Incorporated